pISSN 2234-3806eISSN 2234-3814
Table. 2.
Clinical characteristics and laboratory data of patients with NAFLD according to liver fibrosis stage
| Clinical characteristics | Fibrosis ≤ 2 (N = 79) | Fibrosis > 2 (N = 34) | |
|---|---|---|---|
| Age (yr) | 36.0 (23.5; 50.5) | 61.0 (54.0; 66.0) | < 0.001 |
| BMI (kg/m2) | 29.1 (26.2; 32.3) | 27.6 (25.1; 30.1) | 0.077 |
| DM | 0.007 | ||
| No | 60 (75.9%) | 17 (50.0%) | |
| Yes | 19 (24.1%) | 17 (50.0%) | |
| AST (µkat/L) | 1.1 (0.8; 1.4) | 1.3 (0.8; 2.1) | 0.171 |
| ALT (µkat/L) | 1.7 (1.3; 2.7) | 1.0 (0.6; 1.8) | < 0.001 |
| GGT (µkat/L) | 1.1 (0.8; 1.8) | 1.6 (1.1; 2.6) | 0.013 |
| Albumin (g/L) | 46.8 ± 3.4 | 43.2 ± 4.6 | < 0.001 |
| Platelet (× 109/L) | 249.0 (210.5; 294.5) | 174.5 (137.0; 228.0) | < 0.001 |
| Total cholesterol (mmol/L) | 5.0 (4.3; 5.7) | 4.2 (3.7; 4.9) | 0.005 |
| M2BPGi (COI) | 0.5 (0.3; 0.7) | 1.3 (0.8; 2.2) | < 0.001 |
| NAS | 4.0 (4.0; 5.0) | 5.0 (4.0; 5.0) | 0.314 |
| APRI | 0.7 (0.5; 0.9) | 1.2 (0.8; 1.6) | < 0.001 |
| FIB-4 | 0.9 (0.5; 1.5) | 3.9 (2.5; 5.5) | < 0.001 |
| NFS | -2.9 ± 1.4 | 0.1 ± 1.7 | < 0.001 |
Abbreviations: ALT, alanine aminotransferase; APRI, aspartate aminotransferaseto platelet ratio index; AST, aspartate aminotransferase; BMI, body mass index; COI, cut-off index; DM, diabetes mellitus; FIB-4, fibrosis index based on four factors; GGT, gamma-glutamyl transpeptidase; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD activity score; NFS, NAFLD fibrosis score; M2BPGi, Mac-2 binding protein glycosylation isomer.
Ann Lab Med 2021;41:302~309 https://doi.org/10.3343/alm.2021.41.3.302
© Ann Lab Med